In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 3.9, 5, 26, 26, 9.2 and 11 nM for CDK4, Ark5, PDGFRβ, FGFR1, RET, and Fyn, respectively.
ON123300 is a multi-targeted kinase inhibitor.
The signaling hyperactivation of RTK is most commonly caused by EGFR mutation/amplification or PDGFR amplification/overexpression. FGFR1signaling also occurs in GBM exhibiting FGFR1 kinase domain gain-of-function mutations.
In vitro: In previous study, when Z138C and Granta 519 cells were treated with ON123300, it was found that ON123300 was efficient to inhibit the phosphorylation of Rb family proteins. Moreover, ON123300 was able to inhibit the phosphorylation of proteins that were involved in the PI3K/AKT pathway. In addition, ON123300-treated cells similarly arrested at lower concentrations, however, higher concentrations could lead to the apoptosis induction .
In vivo: Previous animal in vivo study showed that mouse xenograft had a strong inhibition of MCL tumor growth in ON123300-treated animals. Moreover, the treatment with ON123300 to ibrutinib-sensitive and -resistant patient-derived MCLs was able to trigger apoptosis and inhibition of both Rb and PI3K/AKT pathways, indicating that ON123300 could be an effective drug in the treatment of MCL, such as ibrutinib-resistant forms of the disease .
Clinical trial: Up to now, ON12300 is still in the preclinical development stage.
 Divakar SK et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016 Jan;30(1):86-93.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Solubility||≥21.5mg/mL in DMSO with gentle warming|
|Shipping Condition||Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.|
Quality Control & MSDS
- View current batch:
Purity = 99.09%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)